1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Global Alzheimer%s Disease Partnering 2010-2015

Global Alzheimer%s Disease Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Alzheimer’s Disease Partnering 2010-2015 report provides understanding and access to the alzheimer’s disease partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in alzheimer’s disease partnering deals
Top alzheimer’s disease deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Alzheimer ’s Disease Partnering 2010-2015 provides understanding and access to the alzheimer’s disease partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of alzheimer’s disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors alzheimer’s disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 250 links to online copies of actual alzheimer’s disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of alzheimer’s disease partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of alzheimer’s disease technologies and products.

Report scope

Alzheimer’s Disease Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to alzheimer’s disease trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in alzheimer’s disease dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 250 alzheimer’s disease deals
The leading alzheimer’s disease deals by value since 2010

In Alzheimer’s Disease Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Alzheimer's Disease Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of alzheimer's disease deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 250 actual alzheimer's disease deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Alzheimer%s Disease Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in alzheimer's disease partnering

2.1. Introduction
2.2. Alzheimer's disease partnering over the years
2.3. Alzheimer's disease partnering by deal type
2.4. Alzheimer's disease partnering industry sector
2.5. Alzheimer's disease partnering by stage of development
2.6. Alzheimer's disease partnering by technology type

Chapter 3 - Average deal terms for alzheimer's disease

3.1 Introduction
3.2 Average deal terms for alzheimer's disease
3.3 Alzheimer's disease headline values with median calculation
3.4 Alzheimer's disease upfront values with median calculation
3.5 Alzheimer's disease milestone values with median calculation
3.6 Alzheimer's disease royalty rates with median calculation

Chapter 4 - Active alzheimer's disease dealmakers

4.1. Introduction
4.2 Most active alzheimer's disease dealmakers
4.3. Top alzheimer's disease deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Alzheimer's disease dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Alzheimer's disease partnering since 2010
Figure 2: Alzheimer's disease dealmaking activity- 2010 to 2015
Figure 3: Alzheimer's disease partnering by deal type since 2010
Figure 4: Alzheimer's disease partnering by industry sector since 2010
Figure 5: Alzheimer's disease partnering by stage of development since 2010
Figure 6: Alzheimer's disease partnering by technology type since 2010
Figure 7: Alzheimer's disease deals with a headline value
Figure 8: Alzheimer's disease deals with upfront payment values
Figure 9: Alzheimer's disease deals with milestone payments
Figure 10: Alzheimer's disease deals with royalty rates, %
Figure 11: Top alzheimer's disease deals by value since 2010
Figure 12: Big pharma - top 50 - alzheimer's disease deals 2010 to 2015
Figure 13: Big pharma alzheimer's disease deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - alzheimer's disease deals 2010 to 2015
Figure 15: Big biotech alzheimer's disease deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.